Oslo, Norway, 6 February 2026. Reference is made to the stock exchange announcement published 5 February 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, announcing that:  GE Medical Holding AB (“GEMH”), a subsidiary of GE HealthCare Technologies Inc., confirmed that it will exercise all of its 26,973,169 warrants and that remaining warrant holders therefore will have until 26 February 2026 to exercise their warrants (15 business days). Reference is also made to the Company’s stock exchange announcement from the same day, confirming the exercise of warrants by certain leading shareholders and primary insiders in the Company, that together with GEMH, represent approximately 75% of the warrants issued.

In conjunction with the ongoing warrants exercise, the Company will host a global investor call (in English) on Wednesday, 11 February 2026 at 3 PM CET/9:00 AM EST. The presentation will be held by the Company’s CEO, Per Walday; CFO, John Edminson; and CBO, Caspar Foghsgaard.

To attend the webcast, please send an email to: ca@dnbcarnegie.no

A copy of the company presentation will be made available in the Investors section of the Company’s website.

Full press release here

About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com   

For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com